Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 45802-0065-35
Triamcinolone Acetonide 5 mg/g Cream — NDC 45802-0065-35 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Triamcinolone Acetonide 5 mg/g Cream — NDC 45802-065-35 (Billing 45802-0065-35)

by Padagis Israel Pharmaceuticals Ltd · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Triamcinolone Acetonide 5 mg/g Cream from Padagis Israel Pharmaceuticals Ltd, marketed since May 2006 and currently FDA-listed; retail pharmacies pay about $0.1903 per g (NADAC). It is this product's only package size.

NDC 45802-0065-35
🏷️ FDA NDC (as labeled) 45802-065-35 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Past resolved recalls for this product (1)
Class II · Aug 17, 2022 · Terminated — CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness. (Padagis US LLC) · FDA recall D-1497-2022

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-065-35
Product NDC 45802-065
11-digit billing NDC 45802006535
NCPDP billing unit GM — per gram (weight)
RxCUI 1014314, 1085644, 1085686
UNII F446C597KA
Application # ANDA086413
SPL Set ID 5d2fe6c2-3856-47f6-843f-077b2e1080a0
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-05-17
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90550085103720
GPI class Triamcinolone Acetonide
GCN Seq No 007595
GCN 31233
HICL code 002891
Ingredient (HICL) Triamcinolone Acetonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name TRIAMCINOLONE 0.5% CREAM
FDB brand name Triamcinolone Acetonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007595
  • GCN: 31233
  • GPI-14 (Medi-Span): 90550085103720
  • HICL (First Databank): 002891
  • AHFS class code: 48:10.08.00
  • RxCUI (RxNorm): 1014314
Why two NDCs? The FDA registers this code as 45802-065-35 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0065-35. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TRIAMCINOLONE 0.5% CREAM Ingredient Triamcinolone Acetonide
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
  • Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
  • Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
  • Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.190 $2.85 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.3734 $5.60 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3402 $5.10 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.280 $0.189
▼ Down 32% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
45802-0065-35 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE 2006-05-17 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
triamcinolone acetonide 5 mg/g 00168-0002-15 E. 1 tube $0.190 AT Availability likely —
Triamcinolone Acetonide 5 mg/g 16714-0987-01 NorthStar 1 tube $0.190 AT Availability likely —
Triamcinolone Acetonide 5 mg/g 33342-0328-15 Macleods 1 tube $0.190 AT Availability likely —
Triamcinolone Acetonide 5 mg/gthis 45802-0065-35 Padagis 1 tube $0.190 AT Availability likely —
Triamcinolone Acetonide 5 mg/g 67877-0318-15 Ascend 15 g $0.190 AT Availability likely —
Triamcinolone acetonide 5 mg/g 33342-0332-15 Macleods 1 tube $0.275 AT Availability likely +45%
Triamcinolone Acetonide 5 mg/g 45802-0049-35 Padagis 1 tube $0.275 AT Availability likely +45%
Triamcinolone acetonide 5 mg/g 16714-0268-01 NorthStar 1 tube $0.275 AT Availability likely +45%
Triamcinolone Acetonide 5 mg/g 68462-0798-17 Glenmark 1 tube $0.312 — FDA listed +64%
Triderm 5 mg/g 00316-0175-15 Crown 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 50090-2542-00 A-S 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 50090-6533-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 63629-8707-01 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 63629-8785-01 Bryant 15 g — AT FDA listed —
Triamcinolone acetonide 5 mg/g 68071-2294-05 NuCare 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 68071-3810-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 68071-4397-05 NuCare 15 g — AT FDA listed —
Triamcinolone acetonide 5 mg/g 68788-8457-01 Preferred 15 g — AT FDA listed —
triamcinolone acetonide 5 mg/g 68788-8892-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 70518-1094-00 REMEDYREPACK 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 70518-2938-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone acetonide 5 mg/g 71205-0009-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 71335-2714-01 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 72162-1387-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 72162-1836-02 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 76420-0349-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 63187-0495-15 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 71205-0033-15 Proficient 1 tube — — FDA listed —
Triamcinolone Acetonide 5 mg/g 71205-0038-15 Proficient 1 tube — — FDA listed —
Triamcinolone Acetonide 5 mg/g 50090-6211-00 A-S 1 tube — — FDA listed —
Triamcinolone acetonide 5 mg/g 82804-0019-15 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 50090-5980-00 A-S 1 tube — AT FDA listed —
Triamcinolone acetonide 5 mg/g 70518-4205-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone acetonide 5 mg/g 70518-4546-00 REMEDYREPACK 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
May 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS US LLC
FDA applicationANDA086413 (ANDA)
Labeler code45802
First marketedMay 2006
Product typeHuman Prescription Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 59 words ▾

DOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

🤒 Adverse Reactions 60 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

🤰 Pregnancy 97 words ▾

Pregnancy: Teratogenic Effects: Pregnancy Category C - Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 115 words ▾

Pediatric Use - Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

🧬 Clinical Pharmacology 193 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 78 words ▾

HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.025% is available as follows: 15 g tube (NDC 45802- 063 -35) 80 g tube (NDC 45802- 063 -36) 454 g jar (NDC 45802- 063 -05) Triamcinolone Acetonide Cream USP, 0.1% is available as follows: 15 g tube (NDC 45802- 064 -35) 80 g tube (NDC 45802- 064 -36) 454 g jar (NDC 45802- 064 -05) Triamcinolone Acetonide Cream USP, 0.5% is available as follows: 15 g tube (NDC 45802- 065 -35)

📦 Storage and Handling 22 words ▾

STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Manufactured by Padagis ® Yeruham, Israel www.padagis.com Rev 12-24 2N700 RC PH3

📋 Description 91 words ▾

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Triamcinolone acetonide is designated chemically as pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis (oxy)]-,(11ß,16α)-. C 24 H 31 FO 6 , and M.W. of 434.51; CAS Reg.

No. 76-25-5. Each gram of 0.025%, 0.1% and 0.5% Triamcinolone Acetonide Cream USP contains 0.25 mg, 1 mg, or 5 mg triamcinolone acetonide respectively, in a washable cream base of cetyl alcohol, cetyl esters wax, glycerin, glyceryl monostearate, isopropyl palmitate, polysorbate-60, propylene glycol, purified water, sorbic acid, and sorbitan monostearate.

Structural Formula

💬 Information for Patients 126 words ▾

Information for Patients Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.

Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.

3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4.

Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General - Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS-Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted.

If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician.

It is for external use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests The following tests may be helpful in evaluating the HPA axis suppression: urinary free cortisol test ACTH stimulation test Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have had negative results. Pregnancy: Teratogenic Effects: Pregnancy Category C - Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers - It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use - Pediatric patients may demonstra… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 59 words ▾

Nursing Mothers - It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

🧬 Pharmacokinetics 133 words ▾

Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have had negative results.

📄 Package Label / Principal Display Panel 74 words ▾

Principal Display Panel - 0.025% Carton NDC 45802-063-35 Rx Only Triamcinolone Acetonide Cream USP, 0.025% NET WT 15 g Triamcinolone Acetonide Cream USP, 0.025% carton

Principal Display Panel - 0.5% Carton 45802-065-35 Rx Only Triamcinolone Acetonide Cream USP, 0.5% NET WT 15 g Triamcinolone Acetonide Cream USP, 0.5% carton

Package/Label Display Panel - 0.1% Carton NDC 45802-064-35 Rx Only Triamcinolone Acetonide Cream USP, 0.1% NET WT 15 g Triamcinolone Acetonide Cream USP, 0.1% carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
70.3K
Units reimbursed last 4 qtrs
2.4M
Gross reimbursed last 4 qtrs
$905.8K
Avg / prescription
$12.89
Avg / unit
$0.3734
Latest quarter Q1 2026
15.6KRx
Medicaid pays / g
$0.3734
gross reimbursed
vs
NADAC / g
$0.1903
acquisition cost
=
Spread
+$0.1831
+96% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
41% FFS 59% MCO
Fee-for-service · 28,826 Rx Managed care · 41,435 Rx
State Medicaid map
Alaska: 5,445 units · 743 per 100k residents AK Maine: 8,580 units · 615 per 100k residents ME Washington: 75,615 units · 968 per 100k residents WA Idaho: 9,270 units · 472 per 100k residents ID Montana: 4,065 units · 359 per 100k residents MT North Dakota: 720 units · 92.0 per 100k residents ND Minnesota: 21,210 units · 370 per 100k residents MN Wisconsin: 27,089 units · 458 per 100k residents WI Michigan: 85,570 units · 853 per 100k residents MI New York: 69,240 units · 354 per 100k residents NY Vermont: 1,830 units · 283 per 100k residents VT New Hampshire: 3,315 units · 236 per 100k residents NH Oregon: 59,164 units · 1,398 per 100k residents OR Nevada: 56,205 units · 1,760 per 100k residents NV Wyoming: 2,130 units · 365 per 100k residents WY South Dakota: 1,980 units · 215 per 100k residents SD Iowa: 11,640 units · 363 per 100k residents IA Illinois: 41,510 units · 331 per 100k residents IL Indiana: 58,920 units · 859 per 100k residents IN Ohio: 113,587 units · 964 per 100k residents OH Pennsylvania: 65,185 units · 503 per 100k residents PA New Jersey: 11,645 units · 125 per 100k residents NJ Massachusetts: 12,015 units · 172 per 100k residents MA California: 634,943 units · 1,630 per 100k residents CA Utah: 18,480 units · 541 per 100k residents UT Colorado: 47,613 units · 810 per 100k residents CO Nebraska: 6,435 units · 325 per 100k residents NE Missouri: 53,824 units · 869 per 100k residents MO Kentucky: 103,812 units · 2,294 per 100k residents KY West Virginia: 14,835 units · 838 per 100k residents WV Virginia: 52,380 units · 601 per 100k residents VA Maryland: 18,285 units · 296 per 100k residents MD Connecticut: 11,280 units · 312 per 100k residents CT Rhode Island: 2,250 units · 205 per 100k residents RI Arizona: 83,651 units · 1,126 per 100k residents AZ New Mexico: 27,540 units · 1,303 per 100k residents NM Kansas: 9,210 units · 313 per 100k residents KS Arkansas: 16,395 units · 535 per 100k residents AR Tennessee: 43,755 units · 614 per 100k residents TN North Carolina: 56,955 units · 526 per 100k residents NC South Carolina: 31,815 units · 592 per 100k residents SC Delaware: 3,630 units · 352 per 100k residents DE Oklahoma: 30,975 units · 764 per 100k residents OK Louisiana: 52,785 units · 1,154 per 100k residents LA Mississippi: 8,734 units · 297 per 100k residents MS Alabama: 24,795 units · 485 per 100k residents AL Georgia: 48,436 units · 439 per 100k residents GA D.C.: 2,235 units · 329 per 100k residents DC Hawaii: 25,350 units · 1,767 per 100k residents HI Texas: 108,730 units · 356 per 100k residents TX Florida: 139,725 units · 618 per 100k residents FL
Units reimbursed · per 100k residents
92.02,294
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 2,294 /100k
2 Hawaii 1,767 /100k
3 Nevada 1,760 /100k
4 California 1,630 /100k
5 Oregon 1,398 /100k
6 New Mexico 1,303 /100k
7 Louisiana 1,154 /100k
8 Arizona 1,126 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 45802-0064-05 · Padagis 45802-0066-01 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.